← All trials
NCT05238493
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- Feb 14, 2022
- Last posted
- Nov 3, 2022
- Enrollment
- 56
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Veloxis PharmaceuticalsLead sponsor
- Veloxis PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.